New Releases from NCBI BookshelfErdafitinib (Balversa): Therapeutic area: Locally advanced unresectable or metastatic urothelial carcinoma: Reimbursement Review [Internet].​Erdafitinib (Balversa): Therapeutic area: Locally advanced unresectable or metastatic urothelial carcinoma: Reimbursement Review [Internet].

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top